Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIO-001 Formulation Bridging Study in Healthy Volunteers
NCT06170827Phase 1Completed
- Sponsor
- Syneos Health
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SHR-1905 in asthma (2 arms), sponsored by Syneos Health. Primary endpoints: Treatment-emergent Adverse Events, Clinically Significant Changes in Vital Signs and 3 more. Started Nov 2023; status: completed.
02
Drugs
SHR-1905
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06170827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06170827.